199 related articles for article (PubMed ID: 21539750)
1. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion.
Johnson-Holiday C; Singh R; Johnson EL; Grizzle WE; Lillard JW; Singh S
World J Surg Oncol; 2011 May; 9():46. PubMed ID: 21539750
[TBL] [Abstract][Full Text] [Related]
2. CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.
Sharma PK; Singh R; Novakovic KR; Eaton JW; Grizzle WE; Singh S
Int J Cancer; 2010 Nov; 127(9):2020-30. PubMed ID: 20127861
[TBL] [Abstract][Full Text] [Related]
3. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion.
Johnson EL; Singh R; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW; Singh S
J Ovarian Res; 2010 Jun; 3():15. PubMed ID: 20565782
[TBL] [Abstract][Full Text] [Related]
4. CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.
Li B; Wang Z; Zhong Y; Lan J; Li X; Lin H
Med Oncol; 2015 Mar; 32(3):66. PubMed ID: 25691296
[TBL] [Abstract][Full Text] [Related]
5. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.
Johnson-Holiday C; Singh R; Johnson E; Singh S; Stockard CR; Grizzle WE; Lillard JW
Int J Oncol; 2011 May; 38(5):1279-85. PubMed ID: 21344163
[TBL] [Abstract][Full Text] [Related]
6. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.
Johnson EL; Singh R; Singh S; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW
World J Surg Oncol; 2010 Jul; 8():62. PubMed ID: 20649989
[TBL] [Abstract][Full Text] [Related]
7. CCL25/CCR9 interaction promotes the malignant behavior of salivary adenoid cystic carcinoma
Chai S; Wen Z; Zhang R; Bai Y; Liu J; Li J; Kongling W; Chen W; Wang F; Gao L
PeerJ; 2022; 10():e13844. PubMed ID: 36003306
[TBL] [Abstract][Full Text] [Related]
8. CCR9 and CCL25: A review of their roles in tumor promotion.
Xu B; Deng C; Wu X; Ji T; Zhao L; Han Y; Yang W; Qi Y; Wang Z; Yang Z; Yang Y
J Cell Physiol; 2020 Dec; 235(12):9121-9132. PubMed ID: 32401349
[TBL] [Abstract][Full Text] [Related]
9. CCL25/CCR9 Signal Promotes Migration and Invasion in Hepatocellular and Breast Cancer Cell Lines.
Zhang Z; Sun T; Chen Y; Gong S; Sun X; Zou F; Peng R
DNA Cell Biol; 2016 Jul; 35(7):348-57. PubMed ID: 27008282
[TBL] [Abstract][Full Text] [Related]
10. Blocking of c-FLIP(L)--independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction.
Youn BS; Kim YJ; Mantel C; Yu KY; Broxmeyer HE
Blood; 2001 Aug; 98(4):925-33. PubMed ID: 11493434
[TBL] [Abstract][Full Text] [Related]
11. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.
Singh R; Stockard CR; Grizzle WE; Lillard JW; Singh S
Int J Oncol; 2011 Aug; 39(2):373-81. PubMed ID: 21637913
[TBL] [Abstract][Full Text] [Related]
12. Expression and functional role of CCR9 in prostate cancer cell migration and invasion.
Singh S; Singh UP; Stiles JK; Grizzle WE; Lillard JW
Clin Cancer Res; 2004 Dec; 10(24):8743-50. PubMed ID: 15623660
[TBL] [Abstract][Full Text] [Related]
13. The role of the CCL25-CCR9 axis in beta-cell function: potential for therapeutic intervention in type 2 diabetes.
Atanes P; Lee V; Huang GC; Persaud SJ
Metabolism; 2020 Dec; 113():154394. PubMed ID: 33058852
[TBL] [Abstract][Full Text] [Related]
14. CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist.
Lee S; Heinrich EL; Li L; Lu J; Choi AH; Levy RA; Wagner JE; Yip ML; Vaidehi N; Kim J
Mol Oncol; 2015 Oct; 9(8):1599-611. PubMed ID: 26003048
[TBL] [Abstract][Full Text] [Related]
15. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
[TBL] [Abstract][Full Text] [Related]
16. CCL25 chemokine-guided stem cell attraction: an assessment of possible benefits and risks.
Spinnen J; Ringe J; Sittinger M
Regen Med; 2018 Oct; 13(7):833-844. PubMed ID: 30284497
[TBL] [Abstract][Full Text] [Related]
17. Wnt5a and CCL25 promote adult T-cell acute lymphoblastic leukemia cell migration, invasion and metastasis.
Deng X; Tu Z; Xiong M; Tembo K; Zhou L; Liu P; Pan S; Xiong J; Yang X; Leng J; Zhang Q; Xiao R; Zhang Q
Oncotarget; 2017 Jun; 8(24):39033-39047. PubMed ID: 28380463
[TBL] [Abstract][Full Text] [Related]
18. CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice.
Zhu S; Bing Y; Wang X; Yu Q; Wang Y; Xu S; Song L; Wang X; Xia B; Zhu Y; Zhou R
PLoS One; 2014; 9(6):e100167. PubMed ID: 24936795
[TBL] [Abstract][Full Text] [Related]
19. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease.
Apostolaki M; Manoloukos M; Roulis M; Wurbel MA; Müller W; Papadakis KA; Kontoyiannis DL; Malissen B; Kollias G
Gastroenterology; 2008 Jun; 134(7):2025-35. PubMed ID: 18439426
[TBL] [Abstract][Full Text] [Related]
20. LINC00853 restrains T cell acute lymphoblastic leukemia invasion and infiltration by regulating CCR9/CCL25.
Li J; Muhammad J; Xie T; Sun J; Lei Y; Wei Z; Pan S; Qin H; Shao L; Jiang D; Zhang Q
Mol Immunol; 2021 Dec; 140():267-275. PubMed ID: 34808497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
